269
Participants
Start Date
December 3, 2021
Primary Completion Date
April 15, 2022
Study Completion Date
April 15, 2022
Saxenda®
"Patients will be treated with commercially available Saxenda® according to local label and to routine clinical practice at the discretion of the treating physician.~The indication is for adults who need help managing their weight based on two different body mass index (BMI) groups."
Novo Nordisk Investigational Site, Soeborg
Lead Sponsor
Novo Nordisk A/S
INDUSTRY